Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163430 | 1.00 | MAOB (0.32) | MAOBGRIA2GRIA4TRPM8MAOA | |
| SCHEMBL2164735 | 0.90 | GRIA2 (0.31) | MAOBGRIA2GRIA4TRPM8MAOA | |
| SCHEMBL2164739 | 0.90 | GRIA2 (0.31) | MAOBGRIA2GRIA4TRPM8MAOA | |
| SCHEMBL2164035 | 0.86 | TRPM8 (0.31) | MAOBGRIA2GRIA4TRPM8 | |
| SCHEMBL2164040 | 0.86 | TRPM8 (0.31) | MAOBGRIA2GRIA4TRPM8 | |
| SCHEMBL2163931 | 0.82 | FABP3 (0.36) | MAOBGRIA2GRIA4TRPM8MAOA | |
| SCHEMBL2164066 | 0.82 | FABP3 (0.36) | MAOBGRIA2GRIA4TRPM8MAOA | |
| SCHEMBL2163871 | 0.82 | GCGR (0.31) | GRIA2GRIA4 | |
| SCHEMBL2163878 | 0.82 | GCGR (0.31) | GRIA2GRIA4 | |
| SCHEMBL2164589 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | MAOB 1969/4885GRIA2 1267/4885GRIA4 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.